Flossonics
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Seed | |
$5.0m | Seed | ||
$25.0k | Grant | ||
$30.0k | Grant | ||
$25.0k | Grant | ||
N/A | $25.0k | Grant | |
N/A | Grant | ||
* | CAD1.1m | Seed | |
* | $14.0m | Early VC | |
* | $20.0m | Series C | |
Total Funding | AUD61.7m |
Recent News about Flossonics
EditFlosonics Medical specializes in non-invasive hemodynamic monitoring solutions designed to enhance patient care through advanced medical technology. The company primarily serves healthcare providers, including hospitals and clinics, operating within the medical technology (MedTech) sector. Flosonics Medical's core product is a non-invasive device that monitors hemodynamic parameters, which are critical for assessing the cardiovascular health of patients. This technology is particularly valuable in critical care settings where real-time monitoring can significantly impact patient outcomes.
The business model of Flosonics Medical revolves around the development, manufacturing, and sale of its proprietary monitoring devices. Revenue is generated through the direct sale of these devices to healthcare institutions and through potential subscription models for ongoing software updates and maintenance services. The company also benefits from strategic partnerships and participation in accelerator programs, which provide both funding and mentorship to scale their operations.
Flosonics Medical has successfully secured a $5 million seed round funding and has been accepted into prestigious programs like the Lazaridis Scale Up Program and the MedTech Innovator Accelerator Program. These achievements underscore the company's potential for growth and innovation in the MedTech industry.
Keywords: hemodynamic monitoring, non-invasive, MedTech, patient care, cardiovascular health, critical care, medical technology, healthcare providers, seed funding, accelerator programs.